trending Market Intelligence /marketintelligence/en/news-insights/trending/C_6YFaOsGgMtZEBwBHoWqw2 content esgSubNav
In This List

Monopar Therapeutics files for Nasdaq IPO

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Monopar Therapeutics files for Nasdaq IPO

Monopar Therapeutics LLC filed a prospectus with the U.S. Securities Exchange Commission for an IPO of its common shares to raise about $40.3 million.

The Illinois-based company has applied to list its shares on the Nasdaq Capital Market under the symbol MNPR.

Monopar Therapeutics, founded in 2014, plans to use the proceeds from the IPO to advance Validive, a medicine being developed to treat a complication arising from chemotherapy or radiotherapy in patients receiving treatment for oropharyngeal cancer.

JonesTrading Institutional Services LLC is the underwriter for the IPO.